Healthcare
Wuhan General Group (China), Inc.(WUHN)
Live Price
Offline$0.0003
+0.00% today
1Y Change
+200.00%
Window
Jun 23, 2025 โ Jun 9, 2026
- Market Cap
- โ
- Revenue Growth
- -57.4%
- EPS Growth
- -494.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Wuhan General Group (China), Inc. (WUHN) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 200.0% across the available one-year price window (Jun 23, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of -57.4%, EPS growth of -494.9%, a dividend yield of 0.0%. What stands out right now is revenue -57.4%, EPS -494.9%, free cash flow -3251.2% with operating margin -11882.9% and ROIC -254.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WUHN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-57.4% vs +7.6% peer median
Operating Margin
Below sector median
-11882.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2012 was reported on Nov 19, 2012, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -57.4% and EPS is at -494.9%, with operating margin around -11882.9%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WUHN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
WUHN Max Drawdown
-75.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WUHN and SPY.
Company Overview
Wuhan General Group (China), Inc.
Other OTC
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.
- Leadership
- Jeffrey Robinson
- IPO Date
- Apr 19, 2006
- Employees
- 700
- Street Address
- 6500 Transcanada hwy
- Mailing
- Pointe-Claire, QC, H9R 0A5
- Region
- Pointe-Claire, QC, CA
- Reporting Currency
- USD
- Investor Line
- 514-928-7368
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.0
- Price/Sales
- 1.2
- Price/Book
- 0.0
Growth
- Revenue
- -57.4%
- EPS
- -494.9%
- Free Cash Flow
- -3251.2%
Profitability
- Gross Margin
- 9.7%
- Operating Margin
- -11882.9%
- Net Margin
- -12086.9%
- ROE
- -316.1%
- ROIC
- -254.7%
Balance Sheet
- Debt/Equity
- 0.15
- Current Ratio
- 3.18
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.